Cargando…

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

BACKGROUND: Myelotoxicity during initial cycles of chemotherapy for Hodgkin lymphoma is associated with better outcome, supporting the concept of individualised dosing based on pharmacodynamic end points to optimise results. This study was performed to identify the maximum tolerated dose (MTD) of do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibb, A, Greystoke, A, Ranson, M, Linton, K, Neeson, S, Hampson, G, Illidge, T, Smith, E, Dive, C, Pettitt, A, Lister, A, Johnson, P, Radford, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833204/ https://www.ncbi.nlm.nih.gov/pubmed/24136151 http://dx.doi.org/10.1038/bjc.2013.605

Ejemplares similares

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
por: Gangopadhyay, Aparna, et al.
Publicado: (2012)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
por: Bond, David A., et al.
Publicado: (2019)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
por: Suwanban, Tawatchai, et al.
Publicado: (2023)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
por: Subbiah, Vivek, et al.
Publicado: (2007)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
por: Yonezawa, Ryo, et al.
Publicado: (2023)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
por: Dickinson, Michael, et al.
Publicado: (2023)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
por: Cotteret, Camille, et al.
Publicado: (2020)

Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
por: Makiyama, Junya, et al.
Publicado: (2020)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
por: DeBoer, Rebecca J., et al.
Publicado: (2020)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD
por: Chakraborty, Rajshekhar, et al.
Publicado: (2015)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
por: André, Marc P. E., et al.
Publicado: (2020)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
por: Honoré, Bent, et al.
Publicado: (2022)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
por: Pavlovsky, A., et al.
Publicado: (2022)

Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
por: Russell, James, et al.
Publicado: (2021)

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors
por: Cooke, R, et al.
Publicado: (2013)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease
por: Ciccarone, Mariavita, et al.
Publicado: (2023)

P1082: SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA
por: Fiad, N. L., et al.
Publicado: (2022)

The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy
por: Brusamolino, Ercole, et al.
Publicado: (2012)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
por: Santisteban-Espejo, Antonio, et al.
Publicado: (2022)

P067: A pilot of lung cancer screening for survivors of Hodgkin lymphoma
por: Broadbent, Rachel, et al.
Publicado: (2022)

Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study
por: Broadbent, Rachel, et al.
Publicado: (2022)

Biomarkers of apoptosis
por: Ward, T H, et al.
Publicado: (2008)

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7hmpef2oucjd1it0epd7rm9rdc